study

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based TechnologyPeer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature…

1 hour ago
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory studyPress Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

2 days ago
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible UrticariaJasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…

4 days ago
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary VesselsFondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in…

4 days ago
Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH StudyMicrotech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study

Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of its FIH Study

TEL AVIV, Israel, June 9, 2025 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, is happy to announce the…

1 week ago
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlignFutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and…

2 weeks ago
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathyERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

2 weeks ago
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

2 weeks ago
OTM recognised as the Leading Travel Trade Show in India and Asia, for the Second Year in a Row, in a custom study commissioned by Fairfest Media and conducted by NielsenIQOTM recognised as the Leading Travel Trade Show in India and Asia, for the Second Year in a Row, in a custom study commissioned by Fairfest Media and conducted by NielsenIQ

OTM recognised as the Leading Travel Trade Show in India and Asia, for the Second Year in a Row, in a custom study commissioned by Fairfest Media and conducted by NielsenIQ

The customised study, commissioned by Fairfest Media and conducted by NielsenIQ, the leader in consumer intelligence, indicated that travel industry…

2 weeks ago
Chandigarh University Fulfills Dreams of 388 students for Study in USA, 59 students in Australia, 48 students in Canada & 13 students in UKChandigarh University Fulfills Dreams of 388 students for Study in USA, 59 students in Australia, 48 students in Canada & 13 students in UK

Chandigarh University Fulfills Dreams of 388 students for Study in USA, 59 students in Australia, 48 students in Canada & 13 students in UK

CU Empowers Students with Global Exposure from Harvard to Walt Disney World CHANDIGARH, India, June 2, 2025 /PRNewswire/ -- Chandigarh:…

2 weeks ago
Show more Posts